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ABSTRACT 
  
Background: The etiological basis of glioma is poorly understood. We have used genetic markers in a 
Mendelian Randomisation (MR) framework to examine if lifestyle, cardiometabolic and inflammatory 
factors influence the risk of glioma. This methodology reduces bias from confounding and is not 
affected by reverse causation. 
 
Methods: We identified genetic instruments for 37 potentially modifiable risk factors and evaluated 
their association with glioma risk using data from a genome-wide association study of 12,488 glioma 
patients and 18,169 controls. We used the estimated odds ratio of glioma associated with each of the 
genetically defined traits to infer evidence for a causal relationship with the following exposures: 
lifestyle and dietary factors (height, plasma IGF-1, blood carnitine, blood methionine, blood selenium, 
blood zinc, circulating adiponectin, circulating carotenoids, iron status, serum calcium, vitamin [A1, 
B12, B6, E and 25-hydroxyvitamin D], fatty acids levels [mono-unsaturated, omega-3 and omega-6] 
and circulating fetuin-A); cardiometabolic factors (birth weight, HDL cholesterol, LDL cholesterol, 
total cholesterol, total triglycerides, basal metabolic rate, body fat percentage, body mass index, fasting 
glucose, fasting proinsulin, HbA1C levels, diastolic and systolic blood pressure, waist circumference, 
waist-to-hip ratio) were included; inflammatory factors (C-reactive protein (CRP), plasma IL-6 sRa and 
serum IgE).  
 
Results: After correction for the testing of multiple potential risk factors and excluding associations 
driven by one single nucleotide polymorphism (SNP) no significant association with glioma risk was 
observed (i.e. PCorrected > 0.05).  
 
Conclusions: This study did not provide evidence supporting any of the 37 factors examined as having 
a significant influence on glioma risk. 
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IMPORTANCE OF THE STUDY 
 
In this study we attempt to elucidate modifiable risk factors of glioma, the etiological basis of which is 
poorly understood. We used genetic markers in a Mendelian Randomisation (MR) framework to 
examine whether the risk of glioma is influenced by one of 37 lifestyle, cardiometabolic and 
inflammatory factors.  
 
The MR methodology reduces bias from confounding and is not affected by reverse causation, an 
improvement over the traditional observational studies that have previously been conducted. 
Additionally, in this study we leverage the largest glioma GWAS dataset published to-date, giving our 
analysis more power compared to other studies of its type. This improved, unbiased and well powered 
assessment of potential glioma risk factors provides invaluable information to the field. 
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INTRODUCTION 
 
Gliomas account for around 80% of malignant primary brain tumours in adults.1 Gliomas are 
heterogeneous and different tumour subtypes can be broadly classified into glioblastoma (GBM) and 
lower-grade glioma (non-GBM). Gliomas are typically associated with a poor prognosis, irrespective 
of clinical care, with the most common glioma subtype (GBM) being associated with a median overall 
survival of only 12 months.2  
 
While glioma subtypes have distinct molecular profiles presumably resulting from different etiological 
pathways, no environmental exposures have consistently been linked to risk; except for ionizing 
radiation, which only accounts for a very small number of cases.2,3 However, the near threefold higher 
incidence in Northern Europe (6.59 cases per 100,000) than in prosperous Southeast Asia (2.55 cases 
per 100,000) raises the possibility that lifestyle factors influence glioma risk.2,4 Over the last 30 years, 
observational epidemiological studies have sought to establish associations between a variety of 
lifestyle factors and risk of developing glioma. Most studies have focused on factors previously shown 
to influence risk of other cancers, such as diet. Results from these observational epidemiological studies 
have so far either been inconsistent, null or not independently validated; for example the conflicting 
evidence for possible associations with dietary factors and obesity.5–11 In contrast to other cancer types, 
published studies have shown an inverse relationship with both diabetes and hyperglycaemia for 
glioma.12 Studies of a possible relationship between metabolic syndrome traits (triglyceride and 
cholesterol levels, body fat and blood pressure) have produced similarly mixed results.8,13,14 
 
Associations seen in conventional observational studies may not be causal, instead arising as a 
consequence of methodological biases inherent in the study design. Biases include selection bias in 
controls, recall bias, reverse causation or confounding from unmeasured effects.15 Furthermore, the high 
frequency of exposure ascertainment by proxy in studies of glioma represents an additional source of 
bias.16 
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Mendelian randomization (MR) is an analytical approach, whereby germline genetic variants are used 
as proxies, or instrumental variables (IVs), for putative risk factors.17 Since genetic variants are 
randomly assigned at conception, they are not influenced by reverse causation. In the absence of 
pleiotropy (i.e. genetic variants being associated with the disease through alternative pathways) and 
population stratification they can provide unconfounded estimates of disease risk (Figure 1).17 MR can 
therefore mitigate many of the limitations of conventional observational studies and is increasingly 
being used to estimate the impact of an intervention on disease risk.  
 
We have recently used MR to examine possible links between glioma with 25-hydroxyvitamin D levels, 
a common proxy for vitamin D levels, obesity and atopy-related traits.18–20 Here we have extended our 
analysis to examine the relationship of 37 potentially modifiable factors with glioma risk, using a two-
sample MR framework. Genetic variants associated with these 37 factors were identified from the 
largest genome-wide association study (GWAS) conducted to date or meta-analysis of each trait. We 
then evaluated the association of these variants with glioma in a large GWAS comprising 12,488 glioma 
cases and 18,169 control subjects.21 
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METHODS 
 
Two-sample MR was conducted using data from a GWAS of glioma published by Melin et al..21 Ethical 
approval was not sought because these data came from summary statistics and no individual-level data 
were used. 
 
Potentially modifiable risk factors 
The aim of our study was to provide an insight into possible associations between modifiable factors 
which might influence the risk of glioma development. These factors were chosen on the basis of having 
been the subject of a previous investigation or having a role in development of a common cancer (Supp. 
Table 1). Specifically, we considered 19 lifestyle and dietary factors (height, plasma IGF-1, blood 
carnitine, blood methionine, blood selenium, blood zinc, circulating adiponectin, circulating 
carotenoids, iron status, serum calcium, vitamin [A1, B12, B6, E and 25-hydroxyvitamin D], fatty acids 
levels [mono-unsaturated, omega-3 and omega-6] and circulating fetuin-A). Additionally, 15 cardio-
metabolic factors were considered (birth weight, HDL cholesterol, LDL cholesterol, total cholesterol, 
total triglycerides, basal metabolic rate, body fat percentage, body mass index, diastolic blood pressure, 
fasting glucose, fasting proinsulin, HbA1C levels, systolic blood pressure, waist circumference, waist-
to-hip ratio). Lastly, three inflammatory factors (C reactive protein (CRP), IL-6 and serum IgE) were 
used as general markers of systemic inflammation and were included in the hypothesis driven analysis 
(Supp. Table 2).  
 
Genetic instruments for putative risk factors  
The genetic instruments, i.e. SNPs to be used as instrumental variables, were identified from recent 
meta-analyses or the largest GWAS published to date (Supp. Table 3). For each SNP, the chromosome 
position was recovered, the effect estimate expressed in standard deviations (SD) of the trait per-allele 
along with the corresponding standard error. We considered only continuous traits, as analysis of binary 
traits (such as disease status) with binary outcomes in two-sample MR frameworks can result in 
inaccurate causal estimates.18,19 The analysis was restricted to SNPs associated at genome-wide 
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significance (i.e. P ≤ 5 × 10−8) in individuals of European ancestry, to satisfy the MR assumption that 
genetic variants are associated with the modifiable risk factor.22 To avoid co-linearity between SNPs 
for each trait, correlated SNPs were excluded using MR-Base (linkage disequilibrium threshold, r2 ≥ 
0.01) within each trait, with SNPs with the strongest effect size retained.23 These SNPs and their 
associated data are detailed in Supp. Table 3. The process used to generate SNPs used as instrumental 
variables is summarised in Supp. Fig. 1. 
 
Glioma genotyping data  
The association of each genetic instrument with glioma risk was examined using summary effect 
estimates and corresponding standard errors (SEs) from a recent meta-analysis of eight glioma 
GWAS.21 After imputation, this meta-analysis related >10 million genetic variants to glioma in 12,488 
cases (6,183 GBM and 5,820 non-GBM) and 18,169 controls of European descent (Supp. Table 4).  
 
Statistical analysis  
The MR methodology assumes genetic variants used as instruments for a risk factor are only associated 
with the risk factor and not with any confounders or another causal pathway (Figure 1). Furthermore, 
to estimate the size of the causal effect with precision, associations must be linear and not affected by 
statistical interactions.24 The causal effects for each SNP were first estimated using the Wald ratio 
(Supp. Table 5). Where multiple SNPs were available as instruments for the trait, causal effects were 
estimated using an inverse variance weighted fixed-effects (IVW-FE), maximum likelihood estimation 
(MLE), weighted median estimator (WME) and weighted mode-based estimator (WMBE) 
methodologies.17,25,26 We compared the calculated odd ratios and P-values from the four methods to 
assess the stability and validity of associations. Leave-one-out analysis was used to investigate whether 
a particular association was driven solely by a single SNP (Supp. Table 6).27 The MR-Egger regression 
approach was used to evaluate the extent to which directional pleiotropy may affect the causal 
estimates.28 Results were reported as odds ratios (ORSD) with 95% confidence intervals (CIs) per 
genetically predicted SD unit increase in each putative risk factor. To address multiple testing, a 
Bonferroni-corrected P-value of 1.3510-3 (i.e. 0.05/37 putative risk factors) was considered significant, 
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with a 1.3510-3<P-value<0.05 being considered suggestive of an association. The power of MR to 
demonstrate a causal effect depends in part on the proportion of variance in the risk factor explained by 
the genetic variants used as instruments, and we therefore estimated study power for each risk factor a 
priori (Supp. Table 2). Statistical analyses were undertaken using RStudio version 3.4.029 and MR-
Base.23 Figures were produced using Inkscape version 0.92.30  
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RESULTS 
 
Figures 2, 3 and 4 show the association between each of the 37 traits and risk of all glioma, GBM and 
non-GBM tumours respectively, using the Wald ratio and IVW-FE methodologies.  
 
Dietary factors and lifestyle 
There was suggestive evidence of an association between genetically predicted higher basal metabolic 
rate with increased risk of all glioma (ORSD = 1.08, 95% CI: 1.00 - 1.16, P = 0.047) and GBM (ORSD = 
1.13, 95% CI: 1.03 - 1.24, P = 0.009). However, leave-one-out analysis showed the association was 
driven by the SNP rs78378222 at 17p13.3 (Supp. Table 6), a known glioma risk SNP.31 With exclusion 
of rs78378222, no association was observed; glioma (ORSD = 1.04, 95% CI: 0.96 - 1.12, P = 0.319) and 
GBM (ORSD = 1.09, 95% CI: 0.99 - 1.19, P = 0.072). Likewise, the apparent association between 
genetically predicted raised serum calcium levels and a lower risk of glioma (ORSD = 0.84, 95% CI: 
0.71 - 0.98, P = 0.027) and GBM (ORSD = 0.76, 95% CI: 0.62 - 0.92, P = 0.005) was reliant on SNP 
rs780094 (Supp. Table 6). With exclusion of rs780094 the association was non-significant with glioma 
(ORSD = 0.92, 95% CI: 0.69 - 1.23, P = 0.574) and GBM (ORSD = 0.86, 95% CI: 0.60 - 1.22, P = 0.391). 
There was suggestive evidence for genetically predicted higher serum vitamin B6 levels being 
associated with lower risk of all glioma (ORSD = 1.31, 95% CI: 1.06 - 1.62, P = 0.012) and non-GBM 
(ORSD = 1.40, 95% CI: 1.06 – 1.85, P = 0.017), however the observation was again reliant on a single 
SNP (rs4654748). Similarly, the suggestive association between genetically predicted higher blood 
methionine levels and risk of glioma (ORSD = 1.66, 95% CI: 1.13 - 2.45, P = 0.010) and GBM (ORSD = 
1.77, 95% CI: 1.10 - 2.85, P = 0.019) was reliant on a single SNP (rs320485).  
 
The fatty acid (FA) metabolic pathway is complex, with SNPs influencing the metabolism of one FA 
often being associated with circulating concentrations of multiple FAs. To limit bias introduced by 
vertical and horizontal pleiotropy, we restricted our analysis to classes of FAs; such as omega-3 and 
omega-6 polyunsaturated FAs (PUFAs) and monounsaturated FAs (MUFAs), rather than individual 
fatty acids. In this restricted analysis, there was a suggestive association between genetically predicted 
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levels of MUFA with reduced risk of GBM (ORSD = 0.76, 95% CI: 0.63 - 0.91, P = 0.004) and between 
omega-3 PUFA fatty acid levels with reduced risk of glioma (ORSD = 0.83, 95% CI: 0.71 - 0.98, P = 
0.029) and GBM (ORSD = 0.79, 95% CI: 0.65 - 0.97, P = 0.022). Leave-one-out analysis, however, 
revealed that all associations were driven by the same Glucokinase Receptor Protein (GCKR) SNP 
(rs1260326, Supp. Table 6). With the exclusion of this SNP, no association remained significant.  
Circulating adiponectin levels was the only exposure with an observed association with non-GBM risk 
only, (ORSD = 0.74, 95% CI: 0.57 - 0.96, P = 0.022). However, once again leave-one-out analysis 
showed this association was reliant on rs6810075, upon its removal the association did not remain 
significant (ORSD = 0.75, 95% CI: 0.55 – 1.04, P = 0.086).  
 
Genetically predicted circulating levels of carnitine/selenium/zinc/25-hydroxyvitamin-
D/carotenoids/fetuin-A/plasma IGF-I/vitamins (A1, B12 and E), height, iron status and circulating 
levels of mono-unsaturated/omega-3/omega-6 fatty acids showed no evidence for association with risk 
of all glioma, GBM or non-GBM (Figure 2, 3 and 4). 
 
Cardiometabolic and inflammatory factors 
Genetically predicted higher levels of low density lipoprotein (LDL) cholesterol showed suggestive 
evidence of an association with increased risk of glioma (ORSD = 1.10, 95% CI: 1.01 - 1.21, P = 0.035) 
and non-GBM (ORSD = 1.15, 95% CI: 1.02 - 1.30, P = 0.021). This finding contrasts with our earlier 
work which found no evidence for an association, however the previous analysis was based on fewer 
SNPs (26 vs. 44).18 Genetically predicted plasma total triglyceride (TG) also showed a suggestive 
association with risk of GBM (ORSD = 0.87, 95% CI: 0.76 - 0.99, P = 0.030). Leave-one-out analysis 
showed that both LDL and TG associations were unstable. The LDL association being reliant on 
rs2131925 (Supp. Table 6), with exclusion of rs2131925 removing any association - glioma (ORSD = 
1.09, 95% CI: 0.99 - 1.19, P = 0.085) and non-GBM risk (ORSD = 1.12, 95% CI: 0.98 - 1.27, P = 0.090). 
The TG association was reliant on the GCKR SNP (rs1260326, Supp. Table 6); with exclusion of 
rs1260326 also leading to the loss of association - GBM ORSD = 0.93, 95% CI: 0.81 - 1.08, P = 0.360). 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noz209/5609347 by Library Institute of C
ancer R
esearch user on 31 O
ctober 2019
Ac
ce
pte
d M
an
us
cri
pt
 
11 
 
Genetically predicted higher HbA1C levels were also associated with increased glioma risk (ORSD = 
1.28, 95% CI: 1.06 - 1.53, P = 0.010) and non-GBM (ORSD = 1.30, 95% CI: 1.02 – 1.65, P = 0.036). 
However, this association was also reliant on a single SNP (Supp. Table 6), with the exclusion of 
rs16926246 resulting in loss of any association - glioma (ORSD = 1.16, 95% CI: 0.93 - 1.45, P = 0.177) 
and non-GBM risk (ORSD = 1.15, 95% CI: 0.86 – 1.54, P = 0.346). 
 
Genetically predicted total cholesterol was associated with non-GBM risk only (ORSD = 1.14, 95% CI: 
1.01 – 1.28, P = 0.032). However, this association was also reliant on a single SNP (Su p. Table 6b), 
with the exclusion of rs7412 resulting in loss of any association (ORSD = 1.11, 95% CI: 0.97 - 1.27, P 
= 0.116).  
 
Waist-to-hip ratio was associated with non-GBM risk only (ORSD = 1.33, 95% CI: 1.04 – 1.70, P = 
0.022). Leave-one-out analysis of this exposure revealed that removal of any one of three SNPs 
(rs10195252, rs1936805 or rs2820443) reduced the P-value to just above the 0.05 threshold for a 
suggestion of association; (P = 0.059, 0.055 and 0.053 respectively). This was less than the drastic 
reduction seen with the other exposures. 
 
Genetically predicted plasma levels of interleukin-6 (IL-6) receptor subunit alpha (sRa)/C-reactive 
protein (CRP)/high density lipoprotein and serum IgE, birth weight, body fat percentage, body mass 
index, diastolic and systolic blood pressure, fasting glucose and proinsulin levels and waist 
circumference showed no evidence for association with risk of all glioma, GBM or non-GBM (Figure 
2, 3 and 4). 
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DISCUSSION 
 
Despite much research, the etiological basis of glioma has remained elusive. To gain insight into 
possible causal relationships, we have used a MR-based framework to investigate a range of potentially 
modifiable risk factors. Many of the factors and traits have either been the subject of previous 
conventional observational epidemiological studies with varying degrees of support, or are established 
risk factors for multiple common cancers consistent with them having a generic effect on tumour 
development.  
 
A major advantage of the MR approach to establish causal links is the avoidance of biases that can 
influence conventional observational epidemiological studies. A challenge in its implementation is 
exclusion of pleiotropy, where one SNP is seen to effect two seemingly unrelated phenotypic traits, or 
an alternative direct causal pathway being the cause of an association.32 The IVW methodology only 
produces estimates of causal relationship when all genetic variants are valid instruments. To address 
such a shortcoming, and assess the robustness of estimates, as well as implementing IVW we also made 
use of WME and WMBE methods, which can provide unbiased causal effect estimates even when many 
genetic variants are invalid instruments.25,26 While not a case of direct pleiotropy, our analysis did show 
one example of a pleiotropic locus influencing both GCKR SNP (rs1260326) and serum calcium 
(rs780094). However, both of these exposures were discounted after leave-one-out analysis showed 
them both to be reliant on these single SNPs, before the need to investigate the association using WME 
or WMBE methodologies. 
 
None of the 37 potential risk factors we evaluated showed a significant association with glioma risk 
after adjusting for multiple testing (i.e. P < 1.35 × 10-3) although nine showed suggestive evidence (i.e. 
P < 0.05). ORSD and P-values estimated using IVW and MLE methods showed strong agreement with 
respect to the nine suggestively associated factors. Only two exposures showed consistent effect 
estimates across all four analytic methodologies (including WME and WMBE), highlighting the 
instability of any suggested associations identified by one method alone (Supp. Table 5). These 
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consistent exposures were HbA1C levels (GBM and non-GBM only) and serum calcium (GBM only), 
however leave-one-out analysis showed that these associations were reliant on single SNPs, thereby 
calling into question the validity of associations. 
 
We cannot exclude the possibility that some of our findings have been affected by weak instrument 
bias, despite all factors having high F-statistics (>10) (Supp. Table 2). For all glioma, we had sufficient 
power to demonstrate a causal relationship (i.e. >80%) and detect ORSD of 1.33 for all but five risk 
factors. However, we only had >80% power to detect an ORSD of 1.10 for five traits. Moreover, our 
power to demonstrate subtype-specific associations was even more restricted (Supp. Table 2a and 2b 
respectively). Hence, we cannot exclude the possibility that some of the traits examined may have very 
modest effects on glioma risk. 
 
Accepting these caveats, in conclusion our analysis provides no convincing evidence to support any of 
the 37 potentially modifiable factors we examined having a significant association with glioma risk. 
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Supplementary data tables separate SNPs and analysis data by glioma (Supp. Table X), GBM (Supp. 
Table Xa) and non-GBM (Supp. Table Xb). 
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FIGURE LEGENDS 
 
Figure 1: Principles of Mendelian Randomisation (MR) and the assumptions required to obtain 
an unbiased causal effect estimate. The three assumptions are: (1) genetic variants used as 
instrumental variables are only associated with the modifiable risk factor (X); (2) genetic variants only 
influence the risk of developing glioma (Y) through the modifiable risk factor (X); (3) genetic variants 
are not associated with any measured or unmeasured confounders. Single Nucleotide Polymorphism 
(SNP). 
 
Figure 2: Odds ratios for associations between genetically predicted risk factors and glioma. 
Results reported as odds ratios (ORSD) and 95% confidence intervals (CIs) per genetically predicted 
standard deviation (SD) unit increase in the risk factor. A fixed-effects inverse variance weighted (IVW-
FE) method was used to summarize Wald ratio estimates from individual single nucleotide 
polymorphism (SNPs).  P-values suggestive of an association (range: 0.05 – 1.35 x 10-3) indicated by 
*, and significant P-values (< 1.35 x 10-3) indicated by **. Association (Assoc.); IGF: insulin-like 
growth factor; IL-6 sRa: interleukin 6 receptor subunit alpha; IgE: Immunoglobulin E; HbA1C: 
glycated haemoglobin. 
 
Figure 3: Odds ratios for associations between genetically predicted risk factors and 
glioblastoma multiforme (GBM). Results reported as odds ratios (ORSD) and 95% confidence 
intervals (CIs) per genetically predicted standard deviation (SD) unit increase in the risk factor. A 
fixed-effects inverse variance weighted (IVW-FE) method was used to summarize Wald ratio 
estimates from individual single nucleotide polymorphism (SNPs). P-values suggestive of an 
association (range: 0.05 – 1.35 x 10-3) indicated by *, and significant P-values (< 1.35 x 10-3) 
indicated by **. Association (Assoc.); IGF: insulin-like growth factor; IL-6 sRa: interleukin 6 
receptor subunit alpha; IgE: Immunoglobulin E; HbA1C: glycated haemoglobin. 
 
Figure 4: Odds ratios for associations between genetically predicted risk factors and non-GBM. 
Results reported as odds ratios (ORSD) and 95% confidence intervals (CIs) per genetically predicted 
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standard deviation (SD) unit increase in the risk factor. A fixed-effects inverse variance weighted 
(IVW-FE) method was used to summarize Wald ratio estimates from individual single nucleotide 
polymorphism (SNPs). P-values suggestive of an association (range: 0.05 – 1.35 x 10-3) indicated by 
*, and significant P-values (< 1.35 x 10-3) indicated by **. Association (Assoc.); IGF: insulin-like 
growth factor; IL-6 sRa: interleukin 6 receptor subunit alpha; IgE: Immunoglobulin E; HbA1C: 
glycated haemoglobin.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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